Senate pushes national gift registry

Share this article:
At a Senate committee hearing, panelists said drug firms should disclose payments including funding for education, physician travel and food.

The Senate Special Committee on Aging, led by Herb Kohl (D-WI), held the hearing in June to examine physician links with the pharma industry. A national gift registry was discussed, along with stronger adherence to the voluntary American Medical Association and PhRMA gift codes.

“[Sen. Kohl] would like to…bring public disclosure and transparency to the process,” Ashley Glacel, press officer for the senator, told MM&M. “If…these gifts are purely for educational purposes…then of course those industries should not have any hesitancy to have those out in the public domain.”

It was the second time this year that the Senate examined the independence of industry-sponsored CME. In April a Senate Finance Committee report found that the ACCME does not monitor courses or materials for accuracy or evidence of bias (MM&M June 2007).

Presenters can discuss off-label uses for drugs, something that Sens. Max Baucus (D-MT) and Charles Grassley (R-IA), the ranking committee members, worried could be used by a company to expand the market for its product. 

PhRMA and AMA criticized the idea of expanding gift disclosure laws nationally.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.